Please login to the form below

Not currently logged in

Troubled Alkermes eyes November OK for new antipsychotic

Review begins for potential schizophrenia and bipolar I disorder drug

Alkermes logo

The FDA has started its review of Alkermes’ experimental antipsychotic for schizophrenia and bipolar I disorder – ALKS 3831 – setting up a possible approval in November.

ALKS 3831 combines the established oral antipsychotic olanzapine – originally developed and sold by Eli Lilly as Zyprexa but now generically available – with samidorphan, a mu-opioid receptor antagonist designed to counteract olanzapine-associated weight gain.

Dublin-based Alkermes filed for approval of the drug in the US last November, and the FDA has said it expects to make its decision on the drug by 15 November.

Olanzapine is an effective and well-established antipsychotic treatment option for patients with schizophrenia and bipolar, but its clinical use has always been limited by a high risk of weight gain, which results from appetite stimulation.

The increased weight not only heightens patients’ risk of cardiovascular disease, but also reduces their quality of life and can lead to poor compliance with treatment.

The filing of ALKS 3831 is based on two phase 3 studies – ENLIGHTEN-1 and ENLIGHTEN-2 – which showed respectively that Alkermes drug was as effective as olanzapine on its own at controlling schizophrenia symptoms, and that it did so while reducing weight gain.

In ENLIGHTEN-2, patients taking ALKS 3831 had a lower average percent weight gain from enrolment after six months compared with olanzapine, and fewer of them reached the threshold of a 7% increase at that time point.

It’s another stop on the road to recovery for Alkermes, which suffered a major setback last year when the US regulator rejected its antidepressant candidate ALKS-5461 – based on samidorphan and buprenorphine – saying that there wasn’t enough evidence to show it was clinically effective.

The project has since been dropped, and its demise prompted a wave of job cuts at the loss-making biotech later in 2019 in an effort to slash $150m off its annual costs.

That left Alkermes more reliant on a positive outcome for ALKS 3831, its other late-stage development prospect. Shortly after, it agreed a $950m deal to buy Rodin Therapeutics and expand its pipeline with a series of early-stage candidates for synaptopathies such as Alzheimer’s, Parkinson’s and Huntington’s disease.

There have been problems for its already-marketed drugs too, notably an FDA warning letter about misbranding of its addiction therapy Vivitrol (naltrexone) in a print advert.

EvaluatePharma has previously predicted that sales of ALKS 381 could reach $381m in 2024 if approved, which would be a sizeable addition to its current revenues, expected to reach a little over $1.1bn in 2019.

Article by
Phil Taylor

29th January 2020

From: Regulatory



PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...